Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates

Core Insights - Arcutis Biotherapeutics reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.10 per share, and showing improvement from a loss of $0.33 per share a year ago, resulting in an earnings surprise of +160.00% [1] - The company achieved revenues of $99.22 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 14.87% and significantly up from $44.76 million in the same quarter last year [2] - Arcutis Biotherapeutics has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Financial Performance - The company has shown a strong performance in the stock market, with shares increasing approximately 41% since the beginning of the year, compared to the S&P 500's gain of 16.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $99.05 million, and for the current fiscal year, it is -$0.44 on revenues of $332.77 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcutis Biotherapeutics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The performance of Arcutis Biotherapeutics may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than a factor of 2 to 1 [8]